DURHAM, N.C., Feb. 19, 2025– Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. The ELIMINATE-B trial is designed to investigate PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level in patients afflicted with chronic hepatitis B who are HBeAg-negative.
Read the full company press release here.
Source : Precision BioSciences, Inc.
Related HIV and Co-Infections News
-
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences
-
EurekAlert!: Between 2.4 and 4.1 million people estimated to be living with chronic hepatitis B infection in Europe
-
The Rockefeller University: A new mouse model of virus-driven liver cancer may open the door to better diagnosis and treatments
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.